2019 Schneerson-Robbins Prize Awardee
Kathryn M. Edwards
Director, Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, USA
Kathryn M. Edwards, MD is the Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics. Dr. Edwards joined the Vanderbilt Vaccine Program in 1980 and has conducted many pivotal vaccine studies since that time.
View full bio
She has had an extensive experience in leading NIH-funded multicenter initiatives; in designing, conducting, and analyzing pivotal Phase I, II, and III clinical studies on vaccines and therapeutics; in facilitating networking with basic and clinical investigators with a wide range of interests and expertise; and in mentoring many of the young investigators who currently work within her research unit.
She initially focused her efforts on conducting studies of Haemophilus influenzae, type b capsular polysaccharide protein conjugate vaccines in infants within the NIH-funded VTEU. In 1985, she received NIH-funding to conduct a comparative influenza efficacy trial of live attenuated and inactivated influenza vaccines in 3000 children and adults each year for five years. These studies documented the safety and efficacy of both inactivated and live attenuated influenza vaccines in a very large number of children and adults. In 1990, she coordinated the NIH-funded Multicenter Acellular Pertussis Trial comparing 13 different acellular pertussis vaccines produced by different manufacturers throughout the world with two whole cell pertussis vaccines produced in the United States. In these studies, more than 2000 infants were enrolled at six VTEU sites in the United States, and the safety and immunogenicity of the vaccines were compared. In the late 1990s, she conducted additional studies on bacterial vaccines when she studied pneumococcal conjugate vaccines in 260 young infants and determined their role in preventing colonization and disease.
In 1998, Dr. Edwards was awarded a contract from the Centers for Disease Control and Prevention (CDC) to conduct active population-based surveillance to monitor the impact of newly licensed vaccines. In these surveillance efforts, she and her colleagues have determined the burden of many important viral respiratory pathogens, including influenza, RSV, PIV, rhinovirus, coronavirus, and hMPV in both the inpatient and outpatient settings. This surveillance effort was extended to include rotaviral surveillance.
For the past decade, Dr. Edwards has also led the CDC-funded Center for Immunization Safety Assessment (CISA) site at Vanderbilt where she and her colleagues assess adverse events associated with vaccines in subjects of all ages. Dr. Edwards was also awarded a CDC contract in 2011 to conduct comprehensive pneumonia surveillance studies in over 2000 adults and children admitted to Vanderbilt adult and pediatric hospitals and at one other community hospital in Nashville. This generated a large body of published work outlining the etiology and incidence of pneumonia in children and adults.
Dr. Edwards has served on several CDC, NIH, WHO, and IDSA committees. In 2006, she received the IDSA Mentor Award for her exceptional mentoring and in 2014 received the Maureen Andrews Mentoring Award from the Society for Pediatric Research. In 2008 she was elected to the National Academy of Medicine of the National Academy of Sciences. In 2016 she was awarded the Charles Mérieux Vaccinology Award from the National Foundation for Infectious Diseases. In 2018 she was awarded the Maxwell Finland award for Scientific Accomplishments by the National Foundation for Infectious Diseases, and in 2019 she received the Frank Morriss Leadership Award in Pediatrics.
2019 Edward Jenner Lifetime Achievement Awardee
Chief Scientist & Head of External Research and Development, GlaxoSmithKline Vaccines, USA
Rino Rappuoli is Chief Scientist and Head External R&D at GSK Vaccines, based in Siena, Italy and Professor at Imperial College. Prior positions: head of Vaccine R&D at Novartis, CSO of Chiron Corporation, head for R&D at Sclavo.
View full bio
He earned his PhD in Biological Sciences at the University of Siena, Italy, and was visiting scientist at Rockefeller University and Harvard Medical School.
He is elected member of US National Academy of Sciences (NAS), the European Molecular Biology Organization (EMBO), and the Royal Society of London. Awards received: Gold Medal by the Italian President, Albert B Sabin Gold Medal, Canada Gairdner International Award and European Inventor Award for Lifetime Achievement. He was nominated third most influential person worldwide in the field of vaccines (Terrapin). He has published more than 690 works in peer-reviewed journals.
He introduced novel scientific concepts: genetic detoxification; cellular microbiology; reverse vaccinology; pangenome. Developed licensed vaccines: acellular pertussis containing a non-toxic mutant of pertussis toxin; the first conjugate vaccine against meningococcus C; MF59, the first vaccine adjuvant after aluminium salts; meningococcus B; CRM 197 that is used as carrier in many conjugate vaccines.
Dr. Rappuoli is among the world scientific leaders dedicated to the sustainability of global health.
Emergent Biosolutions, USA
Talk Tile: Continued Progress in the Development of a Single-Dose VLP-Based Chikungunya Vaccine
Dr. Bennett is currently Senior Director, Clinical Development at Emergent Biosolutions Inc., a multinational specialty biopharmaceutical company headquartered near Washington DC (USA).
View full bio
Dr. Bennett leads clinical development activities for several vaccine programs, including the live oral cholera vaccine Vaxchora (CVD-103HgR) and rVSV-vectored candidate vaccines against arena- and filoviruses. He has 13 years of experience in the global development of vaccines, anti-infectives and immunomodulators, and previous led the pediatric antiretroviral team at Gilead Sciences Inc. Dr. Bennett earned his MD and PhD (Immunology) degrees at the University of Colorado (Denver CO USA) and trained in pediatrics at Dartmouth-Hitchcock Medical Center (Lebanon NH USA).
Center for Vaccine Innovation and Access PATH, USA
Niranjan Bhat, MD, MHS, is a Senior Medical Officer within the Center for Vaccine Innovation and Access at PATH, currently leading strategy for post-licensure vaccine clinical research.Having received undergraduate and medical education at Harvard and Vanderbilt Universities, respectively, Dr. Bhat completed residency in pediatrics at the University of Washington, Seattle.
View full bio
He then received public health training through the Epidemic Intelligence Service at the US CDC, focusing on influenza, and completed clinical training in pediatric infectious diseases at Johns Hopkins School of Medicine, ultimately joining the faculty in the Department of Pediatrics. Dr. Bhat then moved to the US FDA, serving as a clinical reviewer in the Office of Vaccines, before joining PATH in 2014. At PATH, he has worked on clinical trials and studies and supported policy-making related to a variety of vaccines, including rotavirus, pertussis, meningococcus, Japanese encephalitis, and maternal immunization approaches.
London School of Hygenine and Trop Medicine, UK
Helen Fletcher is a Professor of Immunology at the London School of Hygiene & Tropical Medicine (LSHTM) and Director of International Development, UKRI.
View full bio
Helen is a research group leader at LSHTM where she continues her research in Tuberculosis (TB) vaccines and immune correlates of risk. Since 2000 She has worked with scientists across Africa in The Gambia, Zambia, Ethiopia, Senegal, Kenya, South Africa and Uganda. Helen is co- Principal Investigator of The VALIDATE Network. An MRC/BBSRC GCRF funded Network of UK and LMIC scientists working to develop vaccines for TB, melioidosis, leishmaniasis and leprosy. As Director of International Development Helen is responsible for the development of strategy and the delivery of the Global Challenges Research Fund (GCRF) and Newton programmes.
Helen has a Ph.D in Microbiology from the University of Leeds where she also completed her undergraduate degree. She is co-Editor of the journal Tropical Medicine and International Health and has written over 100 peer review research articles and chapters.
Amsterdam UMC, University of Amsterdam, Netherlands
Vanessa Harris is an Assistant Professor at the Department of Global Health, Amsterdam UMC, University of Amsterdam. She obtained her bachelor’s degree summa cum laude at Amherst College in the United States and then obtained her MD from Harvard Medical School. She was a Fulbright Scholar from 2002-3. She subsequently completed her internal medicine residency and infectious disease fellowship and PhD at the University of Amsterdam in the Netherlands. Her research focuses on understanding the determinants of the diminished efficacy of the oral vaccines in developing countries. She is particularly interested in potential interactions between the infant intestinal microbiome and the rotavirus vaccines. She explores this hypothesis through mouse models, human volunteer studies, and clinical trials. She currently splits her time between Shenzhen, China where she is a clinical consultant at the Hong Kong University-Shenzhen Hospital and Amsterdam.
Hong Kong University, Hong Kong
Professor Ivan Fan Ngai HUNG is currently Ru Chien and Helen Lieh Endowed Professor in Health Sciences Pedagogy, Clinical Professor and Assistant Dean (Admissions), Chief of the Division of Infectious Diseases, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, and Honorary Consultant in Queen Mary Hospital, Hong Kong.
View full bio
Professor Hung is a dual specialist in Infectious Disease and Gastroenterology & Hepatology. He obtained his medical degree from the University of Bristol Medical School, England in 1996. After working in the University of Cambridge Medical School and Charing Cross Hospital, the Imperial College Medical School, London, he returned to Hong Kong in 1999 and joined the Department of Medicine, Queen Mary Hospital. After obtaining his MRCP, he underwent subspecialty training in infectious diseases, followed by gastroenterology and hepatology. He was a Visiting Fellow at the Division of Geographical Medicine and Infectious Diseases, Tufts-New England Medical Center, Boston, USA. He obtained his M.D. degree from HKU in 2011 and was awarded the Sir Patrick Manson Gold Medal award for best M.D. thesis. He was awarded the Richard Yu Lectureship and medal in 2016 by the Hong Kong College of Physicians. He is currently the Fellow of Royal Colleges of Physicians of London and Edinburgh.
Professor Hung has published more than 180 international peer reviewed original articles, including research articles in the Lancet, the Lancet Infectious Diseases and the Clinical Infectious Diseases. He and his team have pioneered the use of topical imiquimod before intradermal influenza vaccination, which results in protection against heterologous non-vaccine and antigenically drifted viruses. His team was also the first to prove convalescent plasma and H-IVIG reduced mortality in patients with severe influenza infection in prospective clinical trials. He is ranked as HKU Scholars in the world top 1% in 2013 and 2018.
University of Chicago, USA
Aaron was born and raised in Bloomfield Hills, MI. He attended the Cranbrook educational community from grades K-12.
View full bio
He studied chemistry at the California Institute of Technology where he first developed a taste for boundary breaking research in the Tirrell lab. After completing his degree, he traveled north to UC Berkeley for a PhD in chemistry as part of the collaborative Chemical-Biology Program and the Francis lab. He completed his postdoctoral training at UIUC working with Jeff Moore and the AMS group. He began his independent career at UC Irvine in 2011 and was promoted with tenure to Associate Professor in 2016. In 2017, he joined the Institute for Molecular Engineering at the University of Chicago.
National Institute of Infectious Disease (NIID), Japan
Hajime KAMIYA MD, MPH, PhD
Senior Researcher, Medical Officer
Division 1, Infectious Disease Surveillance Center,
National Institute of Infectious Diseases
Dr. Hajime Kamiya is a native of Japan. He graduated Mie University School of Medicine in 1999 and trained as a pediatrician at St.Luke’s International Hospital in Tokyo. He was board certificated in pediatrics in 2004.
His interest in immunization posted him to a research fellow at University of California San Diego (UCSD), Department of Pediatrics, with the County of San Diego Health and Human Services Agency, Immunization Branch (SDIB). Since 2006, he became graduate student at Rollins School of Public Health, Emory University, Atlanta GA, where he learned the fundamental of epidemiology.
After graduating from Emory University, he joined National Institute of Infectious Diseases, Infectious Disease Surveillance Center （NIID/IDSC）in Tokyo as a researcher. In 2012, Dr. Kamiya was accepted as Epidemiology Intelligence Service (EIS) officer at Center for Diseases Control and Prevention (CDC). He was assigned to Meningitis and Vaccine Preventable Disease Branch (MVPDB) and experienced outbreak investigation, evidence based policy making, the strategic planning, interventions and evaluation of the immunization program from a federal government aspect.
Dr. Kamiya returned to NIID/IDSC in July 2014 and promoted to Senior Researcher. Based on his experiences in the United States, Dr. Kamiya is directing his training to be a specialist in immunization field.
University of Miami, USA
Dr. Nichole Klatt is an associate professor, vice chair of research, and the Adrienne Arsht Endowed Chair in Pediatric clinical research in the Department of Pediatrics, Miller School of Medicine, and Sylvester Cancer Center of University of Miami. Prior to this,
View full bio
Dr. Klatt was an associate professor in the Department of Pharmaceutics at the University of Washington from 2012-2018. Dr. Klatt received her PhD from Emory University in Immunology and Molecular Pathogenesis in 2009, and was also a visiting PhD candidate at the University of Pennsylvania from 2006-2008. Dr. Klatt performed her postdoctoral research in the Laboratory of Molecular Microbiology at the National Institutes of Health from 2009-2012. The goal of Dr. Klatt’s research laboratory is to understand mechanisms of microbiome and mucosal dysfunction to improve human health. The lab studies the microbiome in host processes in the gastrointestinal tract and female reproductive tract in the context of infectious diseases, pediatric conditions, and cancer.
Icahn School of Medicine at Mount Sinai, USA
More information coming soon...
Hellenic Center for Disease Control and Prevention, Athens, Greece
Dr. Maltezou received her Medical Diploma and her PhD from the University of Crete, Greece, and had her post-doctoral fellowship during 1994-1997 on viral infections in immunocompromised patients at M.D. Anderson Cancer Center, Houston. During 1997-2001 Dr Maltezou was trained at the Pediatric Residency Program of the University of Athens, Greece, and during 2001-2003 in Infectious Diseases at the Universite de la Mediterannee, Marseille, France.
View full bio
In 2003 Dr. Maltezou joined the Hellenic Center for Disease Control and Prevention (Athens, Greece), where, since 2007 serves as the Head of the Department for Interventions in Health-Care Facilities. Her scientific interests include influenza, vaccine-preventable diseases, healthcare-associated infections and emerging infections. Milestones of her research career include the study of Q fever in children, the occupational vaccinations of healthcare workers and the post-partum influenza vaccination. Dr Maltezou has more than 160 articles published in prestigious journals and has edited the English-language book Tropical and Emerging Infectious Diseases. She is the recipient of the 2001 European Society for Paediatric Infectious Diseases Award. In 2016 Dr. Maltezou was honored with the academic title of Guest Professor by the Xi’an Daxing Hospital, China and in 2019 with the academic title of Visiting Professor, University of Catania, Italy.
Director of Biostatistics & Senior Investigator
Biostatistics Unit, Kaiser Permanente Washington Health Research Institute
Affiliate Professor, Department of Biostatistics, University of Washington
View full bio
Jennifer Nelson is Director of Biostatistics and a Senior Investigator at Kaiser Permanente Washington Health Research Institute and an Affiliate Professor of Biostatistics at the University of Washington. Her research focuses on methods to quantify post-market safety and effectiveness for vaccines and drugs, with an emphasis on addressing statistical challenges of using electronic health record data from large health care systems. She has authored over 90 publications, primarily in this area. Since 2009, Dr. Nelson has provided national leadership as Methods Core Lead and Senior Statistician for the U.S. Food and Drug Administration’s (FDA’s) Sentinel Network that facilitates rapid safety surveillance for FDA-regulated medical products. She has also led the Methodology Committee for the Centers for Disease Control and Prevention sponsored Vaccine Safety Datalink (VSD) project, a national multi-site collaboration that has monitored vaccine safety in the U.S. since 1990. Dr. Nelson earned the 2009 VSD Margarette Kolczak Award for outstanding biostatistical contributions in the field of vaccine safety. Her 2013 paper that adapted group sequential monitoring methods to a real-world observational vaccine safety data setting was one of the American Journal of Epidemiology’s Articles of the Year. She received her PhD in Biostatistics at the University of Washington in 1999.
Eng Eong Ooi
Duke-NUS Medical School, Singapore
Professor and Deputy Director, Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore
Professor, SingHealth Duke-NUS Global Health Institute
Eng Eong Ooi trained in medicine at the University of Nottingham Medical School and received his PhD in molecular epidemiology in the Department of Microbiology, National University of Singapore. His research interfaces clinical studies and trials with fundamental virology and immunology towards defining the pathogenic underpinnings of dengue and other related mosquito-borne diseases. These studies have resulted in over 180 publications in peer-reviewed journals, including The Lancet, Science and Nature Medicine. They have also led to translational studies that tested new antiviral treatments and vaccines in six proof-of-concept clinical trials. He is a three-time recipient of the Singapore National Medical Research Council Clinician-Scientist (Senior Investigator) Award.
Infectious Disease Research Institute, USA
Mark Orr is Senior Scientist at the Infectious Disease Research Institute, Vice-President of Immunology at HDT Bio Corp, and Affiliate Assistant Professor of Global Health at the University of Washington.
View full bio
He earned his PhD in Immunology at the University of Washington and completed his postdoctoral fellowship in Immunology & Microbiology at the University of California, San Francisco. His research focuses on the development and understanding of the mechanisms of action of new vaccine adjuvants. His lab studies the mechanisms of immune synergy derived from TLR agonists formulated with inflammasome stimulating formulations and redesigning aluminum salt adjuvants to provide fit-for-purpose immune responses. He has published over 45 peer-reviewed articles on vaccines, adjuvants, and NK cell biology.
Chulalongkorn University, Thailand
Talk Title: Elimination of hepatitis by the year 2030; role of hepatitis vaccines
Prof. Yong Poovorawan is currently Head of the Center of Excellence in Clinical Virology at the Faculty of Medicine, Chulalongkorn University, Bangkok.
View full bio
He obtained the MD in 1974 from Chulalongkorn University and his specialization in pediatrics in 1978 from Chulalongkorn Hospital and University. In 1984, he became a Research Fellow on the field of Paediatric Hepatology at King’s College Hospital Medical School, London. Prof. Poovorawan has been working at Chulalongkorn University, starting off as Lecture and becoming Professor in 1991. He has received many research awards and honors, including the Outstanding Researcher Award in 1997 from the National Research Council of Thailand, Outstanding scientist Award, 1997 from the Foundation for the Promotion of Science and Technology under the Patronage of His Majesty the King, He also received the Outstanding Best Teachers Award in 2004 from the Thailand National University Teacher Association. He is the leader who has been working on Viral hepatitis in Thailand and vaccination studies. He is a member of the EPI vaccine, viral hepatitis and emerging diseases at the Department of Disease control, MoPH. He has authored and co-authored more than 560 publications in the fields of hepatitis, vaccine, and virology with H-index 59 on Google Scholar
National Centre for Infectious Diseases (NCID), Singapore
Dr. Sapna Sadarangani is Infectious Diseases Consultant at the National Centre for Infectious Diseases (NCID), Singapore and co-chair of Singapore’s Paediatric, Obstetric & Neonatal outbreak- preparedness workgroup. Dr. Sadarangani received her medical training (MBBS) at the Yong Loo Lin School of Medicine, National University of Singapore.
View full bio
She completed her Internal Medicine-Paediatrics residency at Western Michigan University in Kalamazoo, Michigan and Infectious Diseases fellowship at the Mayo Clinic, Rochester, Minnesota, where she also participated in translational research related to influenza vaccine with the Vaccine Research Group.
Dr. Sadarangani has research interests in vaccinology, vaccine-preventable diseases, travel medicine, emerging infectious, global health and immune response to vaccines in older adults. Her current research is focused on immunometabolic factors of influenza vaccine immune response in older adults in Singapore supported by intra-mural and National Medical Research Council (Ministry of Health, Singapore) grants. She is a research collaborator with the Vaccine Research Group at Mayo Clinic and fellow of the Academy of Medicine, Singapore.
US Army Medical Component of the Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand
Dr. Schuetz currently serves as Chief of Cellular Immunology at the Department of Retrovirology, US Army Medical Component of the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand. She works under the Henry M. Jackson Foundation as part of the US Military HIV Research Program (MHRP). She received her Ph.D. from the University of Saarland in collaboration with Bayer HealthCare AG, Germany in 2004. After working as a project coordinator at the Fraunhofer Institute for Biomedical Engineering, she started working with MHRP in 2006 and relocated first to Mbeya, Tanzania, where she was Head of Immunology and Specimen Processing. Here she developed in-country research capacity, designed and executed immunology research in the context of HIV vaccine trials and worked on research involving HIV and TB co-infection. In 2008 she moved with MHRP to Bangkok, Thailand and is since then involved in research on acute HIV infection, cure studies and HIV vaccine trials. A major focus of her work is to understand the mechanisms by which HIV infection causes dysfunction of the gastrointestinal and reproductive tract to support development of new cure and vaccine strategies.
WHO Melbourne, Australia
Dr. Kanta Subbarao is the Director of the WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute for Infection and Immunity and Professor, Department of Microbiology and Immunology, The University of Melbourne. She is a virologist and a physician with specialty training in pediatrics and pediatric infectious diseases.
View full bio
Previously, she was Chief of the Emerging Respiratory Viruses Section of the Laboratory of Infectious Diseases, of the National Institute of Allergy and Infectious Diseases (NIAID), NIH in the USA. Dr. Subbarao’ s research has focused on newly emerging viral diseases of global importance including pandemic influenza, severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronaviruses. In her current position, she advises the World Health Organization on viruses to be included in annual seasonal influenza vaccines. Her current research efforts are directed at understanding the biology and immune responses to influenza viruses and vaccines. She is a Fellow of the American Academy of Microbiology and the Infectious Diseases Society of America. She serves on the Editorial Board of PLoS Pathogens and mBio.
Chulalongkorn University, Thailand
Professor Usa Thisyakorn is presently a Professor of Pediatrics and an Executive Director of Tropical Medicine Cluster at Chulalongkorn University, an advisor of Faculty of Tropical Medicine, Mahidol University, Department of Health, Bangkok Metropolitan Administration and Faculty of Medicine, Thammasat University.
View full bio
Her additional positions include Past President of International Society of Tropical Pediatrics, Asian Society for Pediatric Infectious Diseases, Pediatric Society of Thailand as well as Pediatric Infectious Disease Society of Thailand.
In 1989, she received a Rockefeller grant for dengue research at the Centers for Diseases Control and Prevention in Atlanta and Scientific Awards in 1994 from the Elizabeth Glaser Pediatric AIDS Foundation for Pediatric HIV training at the National Institutes of Health in Bethesda. In 2000, under Professor Thisyakorn’s guidance as Chair of the medical committee on the Save a child’s life from AIDS project, the project was selected as one of the UNAIDS best practices in the year 2000. This project has contributed significantly to the recognition of Thailand by the World Health Organization as the first country in Asia to successfully eliminate mother-to-child transmission of HIV in 2015. For her contributions, she has received several awards including Woman of the Year from the Foundation for Thai Society, The OutstandingAsian Pediatrician from the Asia Pacific Pediatric Association and The Outstanding Woman in the International Stage/Network from Ministry of Social Development and Human Security on the occasion of the International Women’s day 2019.
Professor Thisyakorn has served as an editorial board of several medical journals and has contributed over 150 indexed publications to date.
University of Pennsylvania, USA
Drew Weissman received his M.D. and Ph.D. in microbiology from Boston University, Boston, MA. He completed an Internal Medicine residency at the Beth Israel Hospital in Boston and a fellowship in Allergy/Immunology at the NIH.
View full bio
He moved to the Division of Infectious Diseases, Department of Medicine at the University of Pennsylvania in 1997. He is currently a Professor of Medicine at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. His lab developed nucleoside-modified mRNA as a therapeutic protein delivery tool and studies its use in vaccines, therapeutic protein delivery and gene therapy.